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Group 2 innate lymphoid cells (ILC2s) play a critical role in protection against helminths and
in diverse inflammatory diseases by responding to soluble factors such as the alarmin IL-33,
that is often overexpressed in cancer. Nonetheless, regulatory factors that dictate ILC2
functions remain poorly studied. Here, we show that peroxisome proliferator-activated
receptor gamma (PPARγ) is selectively expressed in ILC2s in humans and in mice, acting as a
central functional regulator. Pharmacologic inhibition or genetic deletion of PPARγ in ILC2s
significantly impair IL-33-induced Type-2 cytokine production and mitochondrial fitness.
Further, PPARγ blockade in ILC2s disrupts their pro-tumoral effect induced by IL-33-secreting
cancer cells. Lastly, genetic ablation of PPARγ in ILC2s significantly suppresses tumor growth
in vivo. Our findings highlight a crucial role for PPARγ in supporting the IL-33 dependent pro-
tumorigenic role of ILC2s and suggest that PPARγ can be considered as a druggable pathway
in ILC2s to inhibit their effector functions. Hence, PPARγ targeting might be exploited in
cancer immunotherapy and in other ILC2-driven mediated disorders, such as asthma and
allergy.
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Innate lymphoid cells (ILCs) are the most recently identifiedsubset of innate lymphocytes. ILCs can be classified in threeprincipal groups according to their transcription factor
expression and cytokine secretion, mirroring to some extent CD4
T helper subsets1. Group 1 ILCs (ILC1s) express T-bet and secrete
IFN-γ. Group 2 ILCs (ILC2s) express GATA3 and secrete IL-13
and IL-5. Tissue-resident group 3 ILCs (ILC3s) express RORγT
and secrete IL-22 and IL-17 while, in the human peripheral cir-
culation, ILC3s also comprise a population of progenitor cells
(ILCPs) able to differentiate into all ILC subsets and natural killer
(NK) cells2. In the last few years, different reports highlighted the
important contribution of ILCs to different physiological and
pathophysiologic processes3. In particular, ILC2s have been
reported to play a critical role in several inflammatory diseases
including asthma, chronic rhinosinusitis, and allergic rhinitis4–6.
Moreover, we and others have shown that ILC2s mediate tumor
immune responses, with either pro- or anti-tumor effects
depending on the tumor type7–11. Nonetheless, external and cell-
intrinsic regulatory factors that dictate ILC2 activation and
function remain poorly studied, particularly in humans. Better
knowledge on ILC2-drivers is warranted to enable pharmacolo-
gical interference with ILC2 functions in disease settings. In that
regard, alarmins (e.g., IL-33) were shown to directly activate ST2-
expressing ILC2s and induce their Type-2 cytokine secretion12.
Further, it was reported that certain types of lipids or lipid-
derivatives act as key mediators involved in ILC2 activation. In
particular, in the context of helminth infections, ILC2 function is
dependent on fatty acid synthesis and oxidation, which is known
to be regulated by peroxisome proliferator-activated receptors
(PPARs)13,14. PPARs are a class of nuclear hormone receptors
that act as transcription factors regulating gene expression15.
They are divided in three major isoforms: α, β/δ, and γ that differ
in their tissue expression and functions15. PPARγ regulates the
transcription of genes associated with lipid metabolism and is
expressed in different immune cells, including lymphocytes,
monocytes, dendritic cells, and platelets, where it mainly exerts
anti-inflammatory effects16. Although different synthetic PPARγ
ligands are used in the clinics, 15-deoxy-Δ12-14-PGJ2 (15d-
PGJ2) is one of the few mediators that is often referred as an
endogenous PPARγ ligand17. 15d-PGJ2 is a prostaglandin D2
(PGD2)-derived product that has been reported to be essential for
ILC2 activation18–20. In particular, it has recently been shown
that PGD2 and its metabolites (including 15d-PGJ2) are endo-
genously synthetized after ILC2 stimulation with IL-33, IL-25,
and TSLP19. Furthermore, elevated levels of PPARγ and other
genes involved in prostaglandin (PG) synthesis and response were
recently reported in a single cell mRNA-sequencing analysis of
ILC2s sorted from human tonsil tissue21. In this work, we char-
acterize the expression and functional role of PPARγ in human
and mouse ILCs to assess whether PPARγ can be targeted in the
context of an ILC-directed immunotherapy.
Results
Ex vivo and in vitro expanded human ILC2s specifically express
PPARγ. In order to characterize ILC2s in terms of function and
activation, we mined a previously performed RNA-sequencing
(RNA-seq) analysis of ILC1s, ILC2s, and ILCPs sorted from
healthy donor (HD) PBMCs, and compared their transcriptional
signature (ArrayExpress E-MTAB-8494). In particular, focusing
on fatty acid metabolism-related genes, that have been associated
to ILC2 response during helminthic infection, we found that
PPARγ (PPARG) was more expressed in ILC2s, as compared to
the other ILC subsets (Fig. 1a, left panel), while no differences in
PPARα (PPARA) and PPARβ (PPARD) expression were observed
among the subsets (Fig. 1a, right panel), as also confirmed by
qPCR (Fig. 1b). Similar observations were made by the analysis of
PPAR expression in in vitro expanded ILC subsets, both at
mRNA and protein level (Fig. 1c, d). Given that ILCs are con-
sidered as the innate mirrors of CD4 T helper subsets, we ana-
lyzed the expression of PPARs in the adaptive counterparts of
ILC1s, ILC2s, and ILCPs, i.e., Th1, Th2, and Th17 cells, respec-
tively. PPARγ expression was preferentially observed in human
Th2 and Th17 but not Th1 cells upon expansion (Supplementary
Fig. 1a, d), in contrast to the mouse where PPARγ protein is
expressed predominantly in Th2 cells22. Taken together, these
findings show specific expression of PPARγ in human ILC2s,
which is also maintained during in vitro culture.
PPARγ sustains Type-2 cytokine secretion in human ILC2s. To
better elucidate the functional role of PPARγ in ILC2s, we ana-
lyzed the cytokine production of IL-33/IL-25 (referred as IL)
stimulated ILC2s, after pre-incubation with non-toxic con-
centrations of T0070907, a selective and irreversible PPARγ
antagonist23. As shown in Fig. 2a, b, ILC2s treated with T0070907
produced significantly less IL-13 as compared to control ILC2s.
Moreover, a trend for reduction was also observed for other
ILC2-specific cytokines, including IL-4 and amphiregulin
(AREG) (Fig. 2b)24. These results were confirmed by the quan-
tification of cytokines in cell culture supernatants of ILC2s, pre-
treated or not with T0070907 (Fig. 2c). This additional readout
allowed us to observe that T0070907 not only reduced the
secretion of IL-13 in a concentration-dependent manner (Sup-
plementary Fig. 2a), but also of IL-5 in pre-treated ILC2s
(Fig. 2c). To test if the inhibitory effects of T0070907 were due to
the selective inhibition of PPARγ, we transfected human in vitro
expanded ILC2s with a small interfering RNA (siRNA) targeting
PPARγ. The knockdown of PPARγ was confirmed by qPCR
analysis (Supplementary Fig. 2b). Consistent with the impact of
pharmacological inhibition, PPARγ silencing led to significantly
reduced cytokine production and secretion (Supplementary
Fig. 2c–e). This effect on Type-2 cytokine secretion might be at
least in part a direct consequence of PPARγ binding to peroxi-
some proliferator response elements (PPREs), since we found
motives partially matching the human PPARγ-retinoid X recep-
tor alpha (RXRα) heterodimer binding motif in the promoter
region of both IL-5 and IL-13 genes (Fig. 2d, Supplementary
Data 1). To substantiate this finding, we performed Chromatin
immunoprecipitation (ChIP) on human expanded ILC2s stimu-
lated with the cytokine cocktail and treated or not with T0070907.
The results indicated that PPARγ directly bound to the promoter
of IL-13 in cytokine-activated ILC2s (Supplementary Fig. 2f). An
increasing number of reports demonstrated a direct correlation
between PG synthesis and PPARγ activation25–27. In particular, it
has been recently reported that the inhibition of the cycloox-
ygenase (COX), which is the key rate-limiting enzyme in PG
production, prevents IL-5 and IL-13 secretion by cytokine-
stimulated ILC2s19. Based on these data, we speculated that COX
and PPARγ could exert a synergistic effect on ILC2 cytokine
secretion. Hence, we treated ILC2s with a combination of
T0070907 and celecoxib (CXB), a selective inhibitor of COX-2, a
gene upregulated in ILC2s after cytokine stimulation19. Although
not statistically significant, we observed that this treatment
induced a partial reduction in IL-13 and IL-5 secretion (Supple-
mentary Fig. 2g).
PPARγ inhibition results in mitochondrial dysfunction in
human ILC2s. As a lipid sensor, PPARγ plays a key role in the
regulation of metabolism by affecting, among others, mitochon-
drial biogenesis, glucose uptake, and lipid intake28. To further
dissect the mechanisms underlying the PPARγ-mediated
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Fig. 1 Human ex vivo and in vitro expanded ILC2s specifically express PPARγ. a Heatmap of row z-scores of mRNA level of proteins involved in fatty acid
metabolism (highlighted in italics) or involved in protein-protein interaction with PPARγ (highlighted in bold). Fatty acid metabolism genes were taken from
the “fatty acid metabolic process” Gene Ontology gene set (GO:0006631, http://geneontology.org/). RNA-sequencing counts were transformed to log2
counts per million, and differential gene expression analysis was performed by fitting a linear model to each gene using the voom function in the limma
package for R (v. 3.38.3), followed by a moderated t statistic computation using the empirical Bayes statistics model implemented in the limma package
(See Ercolano et al.1 for detailed methods). Genes significantly upregulated in ILC2s compared to ILC1s and/or ILCPs are indicated using an * (n= 3; *P <
0.05). Proteins putatively involved in protein–protein interactions were taken from the STRING database (https://string-db.org/). b Expression of PPARs
assessed by qPCR in human freshly sorted ILC subsets (open square ILC1s, open circle ILC2s, open triangle ILCPs) (ILC1s n= 6; ILC2s and ILCPs n= 7;
ILC1s vs ILC2s **P= 0.0032, ILC2s vs ILCPs **P= 0.0021). c Expression of PPARs assessed by qPCR in in vitro expanded human ILC subsets (open square
ILC1s, open circle ILC2s, open triangle ILCPs) (ILC1s and ILCPs n= 3; ILC2s n= 5; ILC1s vs ILC2s ****P < 0.0001, ILC2s vs ILCPs *P= 0.0020). d Western
blot analysis of PPARγ expression at protein level in ILC2s compared to ILC1s and ILCPs (one individual experiment). Each symbol represents one individual
donor. Data are shown as mean ± SEM and were analyzed by one- (b) or two-way (c) ANOVA tests. Source data are provided as a Source data file.
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inhibition of ILC2s, we measured mitochondrial mass by Mito-
Tracker Green uptake and MitoTracker Deep Red fluorescence in
these cells. As shown in Fig. 3a–d, both MitoTracker Green and
Deep Red dye uptake were decreased in ILC2s after treatment
with the PPARγ inhibitor, suggesting reduced mitochondrial
mass. We also used tetramethylrhodamine methyl ester (TMRM)
that, by accumulating in intact and active mitochondria, allows to
assess changes in their membrane potential. Consistent with the
MitoTracker results, the TMRM assay showed a significant
decrease of mitochondrial potential after incubation of ILC2s
with T0070907 (Fig. 3e, f). To corroborate our data, we per-
formed electron microscopy (EM) analysis that showed reduced
percentage of mitochondrial volume per cell in T0070907-treated
ILC2s as compared to control (Fig. 3g, h). These findings indicate
that the inhibitory effects of T0070907 correlates with a decline in
mitochondrial function, which in turn likely impairs ILC2 cellular
fitness.
Tumor-derived IL-33 sensitizes ILC2s to produce IL-13. Over
the last decade, alarmins have been identified as signaling med-
iators involved in cancer development and progression29,30. In
particular, different studies reported that IL-33 and its receptor
ST2 play a critical role in the pathogenesis of different types of
cancers, including breast cancer, hepatocellular carcinoma, and
colorectal cancer (CRC)31–34. We used CRC as a model to
address a putative role of tumor-derived IL-33 on ILC2 functions
in the context of tumor immunity. First, we confirmed expression
of IL-33 in human CRC tissues using a Tissue Micro Array
(Fig. 4a). GATA3+CD3− cells were identified in proximity to
IL-33+ CRC epithelial cells, suggesting that IL-33 released from
these malignant cells may stimulate ILC2s in human CRC lesions
(Fig. 4b). In line with these findings, we observed elevated IL-33
levels in the serum of CRC patients as compared to HDs (Fig. 4c).
Next, we evaluated ILC2 frequency and function, in terms of
cytokine production, in both PBMCs and tumor-infiltrating
lymphocytes (TILs) in CRC patients. As previously reported,
circulating ILC2 frequency was comparable in HDs and CRC
patients (Fig. 4d)35. Importantly, ILC2s are present among TILs,
as assessed by flow cytometry analysis of dissociated CRC tissues
(Fig. 4d). In terms of function, ILC2s from CRC patients’ PBMCs
produced more IL-13 compared to ILC2s from HDs’ PBMCs
(Fig. 4e, f). To gain further insight into the role of PPARγ in
ILC2s in the CRC setting, we evaluated the expression of PPARγ,
as well as of CPT1A, one of the well-characterized PPARγ-direct
target genes36, in freshly-sorted ILC2s from both PBMCs and
TILs of CRC patients. As shown in Supplementary Fig. 3a, b, a
trend for higher expression of PPARγ and CPT1A was observed
in CRC patients’ PBMCs compared to HDs, suggesting that
PPARγ is not only increased but also more active in the CRC
setting. In addition, exposure of expanded ILC2s from CRC
patients to T0070907 resulted in the reduction of IL-13 and IL-5
secretion as well as in impairment of mitochondrial functions,
thus recapitulating the effects observed in HD ILC2s (Supple-
mentary Fig. 3c–e). Collectively, these results indicate that ILC2s
from cancer patients are more prone to secrete cytokines, which
may be related to their increased exposure to IL-33, both sys-
temically and in the tumor microenvironment.
IL-13 drives the crosstalk between ILC2s and cancer cells. In the
last few years, IL-13 and its receptors have been identified as
novel targets for cancer therapy, and inhibition of IL-13-
producing cells as a strategy to reach this goal37. To better
Fig. 2 PPARγ sustains Type-2 cytokine secretion in human ILC2s. a Representative example of flow cytometry analysis of ILC2-derived IL-13 upon
treatment (blue dot plot) or not (red dot plot) with T0070907. b Frequencies of Type-2 cytokine positive cells among ILC2s, after treatment (open blue
circle) or not (open red circle) with T0070907 (n= 6; ***P= 0.0002). c Quantification of Type-2 cytokines assessed by Legendplex analysis in cell culture
supernatants of ILC2s upon treatment (open blue circle) or not (open red circle) with T0070907 (n= 6; IL-13 *P= 0.048, IL-5 *P= 0.040). d Location of
motifs similar to the PPARγ-RXRα binding motif (top) in the promoter region of IL-5 and IL-13 (human genome). The motifs with the lowest raw p-value
found by the FIMO tool (blue) or the highest score found by the HOMER software (orange) are shown. The Integrative Genomics Viewer (IGV, v2.8.0) was
used to represent the location of these motifs within the IL-5 and IL-13 promoters84. In b–c each symbol represents one individual donor. Data are shown as
mean ± SEM and were analyzed by two-way ANOVA tests. Source data are provided as a Source data file.
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understand the crosstalk between PPARγ, ILC2s, and the CRC
cells, we pre-treated ILC2s with T0070907 or solvent-control and
co-cultured them with the SW1116 CRC cell line. As shown
in Fig. 5a, b, the ILC2-SW1116 co-culture resulted in increased
IL-13 production by ILC2s that was abolished by pre-treating
ILC2s with T0070907. IL-13 production in ILC2s was possibly
triggered by increased expression of IL-33 in co-cultured CRC
cells (Fig. 5c). To address this hypothesis, we performed co-
culture experiments using the helminth parasite-secreted protein
(HpARI), known to suppress type 2 immune responses through
interference with the IL-33 pathway38. As shown in Supple-
mentary Fig. 4a, the addition of HpARI in the medium sig-
nificantly reduced the production of IL-13 by ILC2s, after co-
culture with SW1116 colorectal cancer cells. Since IL-13 is
involved in CRC progression and metastasis development by
affecting epithelial to mesenchymal transition (EMT)39, we
hypothesized that ILC2-derived IL-13 could affect EMT in CRC
cells. To address this point, we performed wound healing and
clonogenic assays using conditioned medium (CM) of activated
ILC2s, pre-treated or not with T0070907 (ILC2 CM and ILC2+
T0070907, respectively). No effect was observed on the CRC cell
proliferation (Supplementary Fig. 4b). However, we found that
the presence of ILC2 CM increased the migration of SW1116
cells, whereas addition of ILC2+ T0070907 CM lead to the
opposite effect (Fig. 5d, e). Likewise, the colony formation assay
confirmed that ILC2 CM increased the number of SW1116
colonies compared to control and to ILC2+ T0070907 CM
(Fig. 5f). Moreover, the addition of an anti-IL-13 blocking anti-
body abrogated the development of SW1116 colonies, confirming
the involvement of IL-13 in the ILC2-PPARγ dependent effect on
CRC cells (Fig. 5f). In order to corroborate our findings on the
pro-tumor effects of ILC2 CM for the migration and invasion of
CRC, we evaluated in the SW116 line the expression of MMP9
and N-cadherin, two molecules that have been linked to the
progression and invasion of tumor cells40–42. We found that the
addition of ILC2 CM significantly increased the expression of
these two EMT markers on CRC cells, whilst the addition of
ILC2+ T0070907 CM or the anti-IL-13 blocking antibody
reduced their expression towards basal levels (Fig. 5g). Taken
together our data suggest a crosstalk between cancer cells and
ILC2s, in which cancer cells trigger ILC2s to produce IL-13,
which in turn sustains their migratory and invasive capacity, yet
without affecting their proliferation rate. Inhibition of PPARγ in
this circuit thwarts the pro-tumorigenic role of ILC2s.
PPARγ is expressed and functional in murine ILC2s. To
translate our findings into an in vivo setting, we assessed the
expression of PPARg in freshly-sorted ILC subsets from the lung
of C57BL/6 mice. In agreement with our human data, PPARg was
specifically expressed in ILC2s, while it was not detectable in
ILC1s and ILC3s (Fig. 6a). Therefore, we exposed murine ILC2s
to T0070907 in vitro and could thereby recapitulate the results
obtained using human ILC2s, with a reduction in the production
of both IL-13 and IL-5 (Fig. 6b, c). Next, to define the role of
PPARγ in ILC2s beyond its pharmacological inhibition, we used a
transgenic mouse model with an ILC-specific PPARγ inducible
knockout (KO) by crossing Ppargfl/fl animals with mice expres-
sing the Cre enzyme under the Id2 promoter, known to control
ILC development43. This model allows tamoxifen-mediated
induction of Cre activity in time and in an ILC-specific
manner44 (Fig. 6d). We next sensitized Ppargfl/flId2CreERT2
positive or negative mice (also reported as Ppargfl/fl Id2Cre+ and
Ppargfl/fl Id2Cre, respectively) with IL-33 and IL-25 i.p. for 3 days,
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Fig. 3 PPARγ inhibition in ILC2s results in mitochondrial dysfunction. a, c, e Representative examples of flow cytometry analysis of MitoTracker Green
(a) MitoTracker Deep-red (c) and TMRM (e) in ILC2s untreated (gray histograms) and after T0070907 treatment (blue histograms) for 48 h, with their
respective quantification in terms of mean fluorescence intensity (MFI), in b, d, f ILC2s untreated (open circle) and after T0070907 treatment (open aqua
circle), (n= 8; Mitotracker Green *P= 0.0282, Mitotracker Deep Red **P= 0.0019, TMRM **P= 0.0036). Representative electron microscopy images
(×4800 magnification; scale bars: 1 µm) (g) and quantitative plots (h) of mitochondrial volume in ILC2s untreated (open circle) and after T0070907
treatment (open aqua circle) for 48 h (n= 40 cells examined for each experimental condition over one independent experiment; *P= 0.0307). Each
symbol represents one individual donor or one cell. Data are shown as mean ± SEM and were analyzed by two-tailed Wilcoxon tests. Source data are
provided as a Source data file.
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sorted from Ppargfl/fl Id2Cre+ mice secreted significantly less
IL-13 and IL-5 compared to control Ppargfl/fl Id2Cre− mice. In
addition, similarly to the results observed in humans, we found
motives partially matching the mouse PPARγ-Rxrα heterodimer
binding motif in the promoter region of both Il-5 and Il-13 genes
(Fig. 6f, Supplementary Data 2). Taken together these results
confirm the role of PPARγ as a key regulator of ILC2 function
in vivo.
PPARγ expression in ILC2s influences cancer progression in a
CRC murine model. Next, to investigate the in vivo role of
ILC2s in CRC development and progression, we used a het-
erotopic murine model of CRC in RORafl/sgIl7rCre mice
(referred to as ILC2 KO mice)45. We injected subcutaneously
(s.c.) MC-38 murine genetically modified CRC cells to con-
stitutively produce IL-33 (reported as MC-38-IL33). Tumor cells
were injected into the right flank of ILC2 KO and littermate
control mice, and survival was monitored. As displayed in
Fig. 7a, tumor progression was slower in ILC2 KO mice com-
pared to littermate controls, resulting in better survival advan-
tage in the KO strain, suggesting a pro-tumorigenic function of
ILC2s in this model. This effect was reverted after the adoptive
transfer of expanded ILC2s sorted from the lungs of C57BL6
mice (Fig. 7b). Next, to further assess the contribution of PPARγ
to ILC2s during tumorigenesis, we injected MC-38-IL33 cells
into Ppargfl/flId2Cre+ mice and Ppargfl/fl Id2Cre− mice (Fig. 7c).
Strikingly, after 18 days, tumor volume was reduced in Ppargfl/fl
Id2Cre+ mice compared to control (Fig. 7d). In line with these
data, Ppargfl/flId2Cre+ mice showed a longer survival compared
to control mice (Fig. 7e). To confirm our in vitro results on the
involvement of ILC2s in the EMT phenomenon, we evaluated by
qPCR analysis the expression of murine MMP-9 and N-cadherin
in dissociated tumor tissues. As shown in Fig. 7f, higher
expression of both Mmp9 and Ncad in Ppargfl/flId2Cre− com-
pared to Ppargfl/flId2Cre+ tumors were observed. In addition, to
evaluate the therapeutic potential of PPARγ inhibition in CRC
development and progression, we treated tumor-bearing mice
with T0070907. As shown in Supplementary Fig. 6a, treatment
with T0070907 significantly reduced both tumor volume and
weight, suggesting a possible therapeutic use of PPARγ inhibi-
tors in CRC patients. Furthermore, we also assessed the pro-
tumor effects of IL-13 in vivo by treating tumor-bearing mice
with an anti-IL-13 neutralizing antibody. After 18 days of
treatment, both tumor volume and weight were significantly
reduced in treated mice compared to controls (Supplementary
Fig. 6b). Taken together, these results underscore the relevance
of ILC2s and PPARγ in fostering cancer cell progression and
subsequent metastatic potential.
Discussion
ILC2s are emerging as key regulators of Type-2 immune


































































































































Fig. 4 Tumor-derived IL-33 sensitizes ILC2s to produce IL-13. a Representative examples of IL-33+ tumor epithelium in human CRC tissues (one out of
88 stained cores in a CRC tissue microarray) Scale bar: 600 µm. b Representative examples of CRC core stained for IL33 and CD3 (big insert), a magnified
view of the area marked by the black square after both staining have undergone color deconvolution and co-registration (right insert). Scale bars: Big insert:
100 µm small tiles: 50 µmmerge (big tile): 25 µm. c Quantification of IL-33 plasma levels assessed by ELISA in CRC patients (open violet circle) and healthy
donors (open red circle) (HDs) (HD n= 21, CRC Patients n= 15; ***P= 0.0001). d Representative examples and quantification in terms of frequency
and absolute numbers of ILC2s in HD PBMCs (open red circle), CRC patients’ PBMCs (open violet circle) and TILs (closed violet circle) (n= 10).
e Representative example of flow cytometry analysis of ILC2-derived IL-13 in HD PBMCs, CRC patients’ PBMCs or TILs. f Frequencies of IL-13 and IL-5
positive ILC2s in ex-vivo HD PBMCs (open red circle), CRC patients’ PBMCs (open violet circle) or TILs (closed violet circle) (HDs and CRC PBMCs n= 15,
CRC TILs n= 12; IL-13 HD PBMCs vs CRC PBMCs *P= 0.0144, IL-13 HD PBMCs vs CRC TILs **P= 0.0094, IL-5 HD PBMCs vs CRC TILs **P= 0.0044).
Each symbol represents one individual donor. Data are shown as mean ± SEM (*P < 0.05; **P < 0.01, ***P < 0.001) and were analyzed by Wilcoxon (c), one
(d) - or two-way (f) ANOVA tests. Source data are provided as a Source data file.
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homeostasis and disease. However, both extrinsic and cell-
intrinsic regulatory pathways dictating ILC2 functions remain
elusive. Here, we demonstrate that PPARγ is selectively expressed
in ILC2s, both in humans and mice. Its pharmacological inhibi-
tion impairs mitochondrial fitness and reduces Type-2 cytokine
secretion in ILC2s upon IL-33 stimulation. Furthermore, in the
environment of a human IL-33-enriched cancer type, such as
CRC, ILC2s show PPARγ-dependent pro-tumoral functions.
Lastly, by inducible and conditional deletion of PPARγ in ILCs
using PPARgfl/flId2CreERT2 mice and a heterotypic tumor model,
we show significant reduction of cancer development and pro-
gression in vivo. Overall, our results point to a PPARγ-driven
pro-tumorigenic role of ILC2s in IL-33-dependent tumors and
suggest that PPARγ targeting in ILCs may become an attractive
add-on therapy for ILC2-driven diseases, including cancer.
It has been reported that fatty acid metabolism-related genes
(including hexokinase 2 (HK2), pyruvate dehydrogenase kinase 1
(PDK1), and FATP-6 play a key role in ILC2 functions during
helminthic infections13. In other immune cell types, PPARγ was
shown to act as a master regulator of lipid metabolism in alveolar
macrophages46, as inhibitor of pro-inflammatory cytokine
secretion47, and to promote type-2 responses48. In that regard,
Nobs et al. found that IL-33 drives Th2 responses and the
development of pulmonary allergic inflammation by induction of
PPARγ in CD4+ T cells and DCs22. More recently, it has been
reported that Th9 function is positively regulated by PPARγ,
which promotes IL-9 secretion in acute allergic skin diseases49.
Different ILC transcriptomic analysis previously reported on
PPARγ mRNA expression in ILC2s, in both human and mouse
tissues21,50. Moreover, it has been recently reported that PPARγ
is an important regulator of ILC2 during allergic airway
inflammation51,52. In addition, Batyrova et al., demonstrated that
the expression of PD1 on ILC2s is controlled by PPARγ and
affects the production of IL-5 and IL-13 in vivo53. However, the
functional relevance of this nuclear receptor in ILC2s is still
limited, particularly in humans. In contrast to the activation-
induced PPARγ expression in CD4+ Th2 cells22, our results argue
for a steady-state expression of PPARγ in ILC2s, that apparently
acts as an homeostatic regulator of Type-2 cytokine secretion,
likely in the presence of endogenous ligands such as PGD2-
derived 15d-PGJ2, as it was previously reported19. It has been
demonstrated that PPARγ stimulation, via the induction of PGC-
1α, promotes mitochondrial biogenesis in different cell types54.











































































































































































































































































Fig. 5 IL-13 drives the crosstalk between ILC2s and cancer cells. a Representative example of flow cytometry analysis of ILC2-derived IL-13 upon co-
culture with SW1116 CRC cells. b Frequencies of IL-13 and IL-5 positive ILC2s with T0070907 upon co-culture with SW1116 CRC cells ((Medium
(open circle) Medium+ SW1116 (open red circle) Medium+ T0070907+ SW1116 (open blue circle)) (Medium n= 6, Medium+SW1116 n= 8,
Medium+ T0070907+ SW1116 n= 8; Medium vs Medium+ SW1116 *P= 0.0313, Medium+ SW1116 vs Medium+ T0070907+ SW1116 *P= 0.0103).
c Expression of IL-33 assessed by qPCR analysis in SW1116 CRC cells upon co-culture with ILC2s (SW1116 CTR (open circle) SW1116+ ILC2 (open red
circle) SW1116+ ILC2+ T0070907 (open blue circle) (n= 3; *P= 0.0419). d Representative example of a wound healing assay (×20 magnification; Scale
bar: 50 µm) performed using SW1116 CRC cells (CTR (open circle)) after incubation with ILC2 (open red circle) or ILC2+ T0070907 conditioned medium
(CM) (open blue circle). e Quantification of the healed wound area at 24, 48, and 72 h (n= 5; **P= 0.0078, *P= 0.0493). f Representative example and
quantification of clonogenic assays performed using SW1116 CRC cells (open circle) after incubation with ILC2 CM (open red circle), ILC2+ T0070907
CM (open blue circle) or ILC2 CM+ anti-IL-13 blocking antibody (open green circle) for 14 days (SW1116 CTR n= 6, ILC2 CM and ILC2+ T0070907 CM
n= 8, ILC2 CM+ anti-IL13 n= 3; ***P= 0.0002, **P= 0.0085, *P= 0.0497). g Expression of MMP9 (left) and N-cadherin (right) assessed by qPCR
analysis in SW1116 CRC cells (open circle) upon incubation with ILC2 CM (open red circle), ILC2+ T0070907 CM (open blue circle) or ILC2 CM+ anti-IL-
13 blocking antibody (open green circle) (SW1116 CTR, ILC2 CM, ILC2+ T0070907 CM n= 6, ILC2 CM+ anti-IL13 n= 5;MMP9 SW1116 CTR vs ILC2 CM
**P= 0.0035, ILC2 CM vs ILC2+ T0070907 CM *P= 0.0425, ILC2 CM vs ILC2 CM+ anti-IL13 *P= 0.0152; NCAD SW1116 CTR vs ILC2 CM ****P <
0.0001, ILC2 CM vs ILC2+ T0070907 CM **P= 0.0041, ILC2 CM vs ILC2 CM+ anti-IL13 ***P= 0.0002). Each symbol represents one individual donor
or sample. Data are shown as mean ± SEM and were analyzed by one- (c, f, g) or two-way (b, e) ANOVA tests. Source data are provided as a Source
data file.
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maintenance of energetic homeostasis also in ILC2s, possibly by
boosting PGC-1α expression and promoting mitochondrial
activity. Further, the expression of IL-13 and IL-5 could be
directly regulated by the PPARγ-RXRα heterodimer in Type-2
cytokine epigenetically-poised ILC2s55, as suggested by the pre-
sence of potential PPARγRXRα binding elements in the promoter
regions of these genes. Whether or not PPARγ expression is
heterogeneous in distinct developmental stages or/and in sub-
populations of ILC2s across tissues remains to be elucidated by
high-definition screening methods, such as single-cell mRNA
sequencing.
Accumulating evidence has indicated that IL-33 and its
receptor ST2 (also known as IL1RL1) represent a key inflam-
matory pathway in tumor biology and immunology34,56. In
particular, several studies reported that IL-33 and ST2 are
implicated as potent modulators of the TME promoting immune
cells recruitment and tumor malignancy in different types of
cancer, including breast cancer, hepatocellular carcinoma, gastric
cancer, and CRC31,57,58. In CRC, different reports showed that
IL-33 and ST2 are highly expressed in tumor tissues and corre-
lated with tumor development31 or advanced tumor stage and
poor prognosis59–61. ILC2 tumor infiltration has been reported by
us and others in different cancer types, being linked with both
pro- and anti-tumor activities depending on the context10. Sig-
naling through ST2 can directly stimulate Type-2 cytokine pro-
duction by ILC2s62. In turn, ILC2-derived, IL-33-triggered IL-13
was shown to favor myeloid-derived suppressor cells (MDSCs)
induction and to be linked to recurrence in bladder cancer7,57,63.
Moreover, IL-13 has been reported to promote EMT via IL-13R/
STAT6 signaling, but nothing was previously reported on a
possible link between EMT and ILCs39. Our results show that
ILC2s exert an essential role in the tumor-driven IL-33/ST2/IL-13
axis, by promoting the migration and invasion of CRC cancer
cells, which are key factors promoting metastasis in vivo64. Our
results indicate that PPARγ is key in this interaction between
ILC2s and cancer cells, by supporting ILC2s in their pro-tumoral
functions, that might be conserved across different IL-33
dependent tumors, such as breast and liver cancer. However, in
other tumor types, ILC2s might exert anti-tumor functions, thus
arguing that the benefit of targeting ILC2s is tumor type-
dependent65. To date, conflicting data have been reported on
PPARγ in cancer development and progression66. On the one
hand, PPARγ expression has been associated with good prognosis
in CRC67 and the use of the PPARγ agonists troglitazone and
rosiglitazone inhibited tumorigenesis in CRC and bladder cancer
models by a tumor-directed effect68,69. On the other hand, in
Apcmin mice the same treatment increases the number of tumors,
and the use of PPARγ inhibitors (including T0070907) sup-
pressed breast cancer cell proliferation in vitro70 and restrained
CRC cell migration and invasion both in vitro and in vivo71,72. In
our setting of PPARγ targeting in ILC2s, the observed anti-
tumoral phenotype obtained by the in vivo conditional and
inducible genetic deletion of PPARγ in ILCs suggests that ILC-
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Fig. 6 PPARγ is expressed and functional in mouse ILC2s. a Expression of Pparg assessed by qPCR analysis in freshly-sorted ILC subsets from the lung of
C57BL6 mice (n= 3). b Representative example of flow cytometry analysis of mouse ILC2-derived IL-13 upon T0070907 treatment in vitro. c Frequencies
of IL-13 and IL-5 positive ILC2s untreated (open red circle) and after T0070907 treatment (open blue circle) (n= 4; *P= 0.0101, **P= 0.0015).
d Expression of Pparg assessed by qPCR analysis in freshly-sorted ILC2s from the lung of IL-33/IL-25-treated Ppargfl/flId2CreERT2 positive (open blue
circle) or CreERT2 negative mice (open red circle) (n= 10, **P= 0.0098). e Quantification of IL-13 and IL-5 assessed by Legendplex analysis in cell culture
supernatants of murine ILC2s upon stimulation with IL-33 and IL-25 in vitro (Ppargfl/flId2CreERT2 positive (open blue circle) or CreERT2 negative mice
(open red circle)) (Ppargfl/flId2CreERT2 negative n= 11, Ppargfl/flId2CreERT2 positive n= 14; IL-13 **P= 0.0086, IL-5 **P= 0.0035). f Location of motives
similar to the PPARγ-RXRα binding motif (top) in the promoter region of IL-5 and IL-13 (mouse genome). The motives with the lowest raw p-value found by
the FIMO tool (blue) or the highest score found by the HOMER software (orange) are shown. The Integrative Genomics Viewer (IGV, v2.8.0) was used to
represent the location of these motifs within the IL-5 and IL-13 promoters84. See Supplementary Data 2 for complete motif search results. Each symbol
represents one individual mouse. Data are shown as mean ± SEM and were analyzed by Wilcoxon (d) or two-way (c, e) ANOVA tests. Source data are
provided as a Source data file.
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cancer. Thus, we identified PPARγ as a druggable target to sup-
press the potent and rapid ILC2 effector functions. Its pharma-
cologic inhibition might be used as an add-on therapy for cancer
treatment and/or in other ILC2-mediated diseases, as recently
demonstrated in allergy and asthma22,48,73.
Methods
Human peripheral blood cell collection. Venous blood was drawn from healthy
donors (HDs) at the Swiss Transfusion Center CRS of Lausanne, Volunteers are
asked to read an information sheet for blood donation and to complete an online
medical questionnaire on the day of donation. Once the questionnaire finalized, a
PDF file is generated for printing, and it is signed to give the approval of the blood
donation. PBMCs were isolated by Lymphoprep (Stemcell) centrifugation and
immediately cryopreserved.
CRC patients. Donors of CRC tissues gave written informed agreement and
analyses of the samples were approved by the Cantonal Ethics Committee of Bern
(2017-01821 and 2018-01502). Leftover material from diagnostic was used for the
tissue microarray (TMA), no extra tissue was collected specifically for this study.
Metastatic colorectal cancer patients were included in the “Epitopes-CRC01”
(NCT02838381) and “Epitopes-CRC02” (NCT02817178) trials, two French mul-
ticentric prospective studies. Epitopes CRC02 (n= 256, NCT02817178) and Epi-
topes CRC01 (ongoing, NCT02838381) are observational studies performed on
first-line metastatic colorectal cancer patients. Given that peripheral blood and
tissue sampling was performed in both studies, they were retrospectively registered
as interventional at ClinicalTrials.gov. However, the patients didn’t receive any
additional intervention than standard of care. These two studies involved the
collection of PBMC and tumor tissue. Epitopes CRC01 included several observa-
tional cohorts while Epitopes CRC02 was constituted by only one observational
cohort. Samples included in this study were either from cohort A (patient with
metastatic colorectal cancer with first-line therapy by chemotherapy +/− surgery
and with a disease-free survival > or = at 20 months) of the Epitopes CRC01 study,
or from the Epitopes CRC02 study. All patients were enrolled after the signature of
an informed consent, in accordance with the French regulation and after the
approval by the local and national ethics committee (CPP Grand Est II). Data were
anonymized. For each patient from “Epitopes-CRC02” (NCT02817178) trial, blood
samples were collected before any metastatic cancer specific treatment. For patients
from “Epitopes-CRC01” (NCT02838381), tumor samples were excised by surgeons
from the department of digestive surgery at University Hospital Besançon.
The generation of TIL cultures was based on the methodology previously
established by Dudley et al.74.
We have complied with all relevant ethical regulations for work with human
participants, and we confirm that informed consent was obtained from each donor.
Flow cytometry analysis. Human ILCs were identified as lineage (Lin) negative
and CD127 positive cells. Lineage markers, all FITC-conjugated, include: anti-
human CD3 (UCHT1, Beckman Coulter (BC) 1:50), anti-human CD4
(SFCI12T4D11, BC, 2:50), anti-human CD8 (MEM- 31, Immunotools, 1:50), anti-
human CD14 (RMO52, BC, 2:50), anti-human CD15 (80H5, BC, 2:50), anti-
human CD16 (3G8, BC, 1:100), anti-human CD19 (J3-119, BC, 1:100), anti-human
CD20 (2H7, Biolegend, 1:100), anti-human CD33 (HIM3-4, Biolegend, 1:50), anti-
human CD34 (561, Biolegend, 1:100), anti-human CD203c (E-NPP3, 1:50)
(NP4D6, Biolegend, 2:50), anti-human FcεRIα (AER-37, Biolegend 2:50) anti-
human CD56 (REA196, Miltenyi, 1:50). Additional markers used include: Brilliant
Violet 421 anti-human CD127 (IL-7Rα) (A019D5, Biolegend, 1:100), APC anti-
human CD117 (cKit) (YB5.B8, BD Bioscience, 1:50), PE anti-human CRTH2
(CD294) (BM16, Biolegend, 1:50). Dead cells were excluded using the viability dye
Live/Dead Aqua or Vivid IR (Invitrogen). Representative gating strategy is included
in Supplementary Fig. 7a. Intracellular staining was performed after fixation and
permeabilization with 0.1% saponin (Sigma), using PE-Cy7 (JES10-5A2, Biolegend,
1:50) or PE anti-human IL-13 (7118582, BD Bioscience, 2:50) Alexa Fluor 700 anti-
human AREG (In-house, 2:50) PE anti-human IL-4 (11B11, Biolegend, 1:50) and
Brilliant Violet 421 anti-human IL-5 (TRFK5, Biolegend, 1:50). Samples were
acquired on Gallios flow cytometer (Beckman Coulter) or LSR-II (Becton-Dick-
inson, San Jose, CA) and data were analyzed using FlowJo software (TreeStar
V.10). For ILC isolation, aliquots of cells were sorted to 98% purity using a
FACSAria (Becton Dickinson). For mitochondrial activity, ILC2s from healthy
donors were stained by: MitoTracker Green (M7514 ThermoFisher), MitoTracker
Deep Red (M22426, ThermoFisher), TMRM (T668, ThermoFisher).
Human CD4+ T cell subsets were isolated by FACS using the following antibodies:











































































































































































Fig. 7 PPARγ expression in ILC2s influences cancer progression in a CRC murine model. a Tumor survival of RORafl/sgIl7rCre positive (blue bar) or
negative (red bar) mice after implantation of MC-38-IL33 murine CRC cells (ILC2 WT n= 6, ILC2 KO n= 7; *P= 0.0227). b Representative image of
tumor size (left) and tumor development (right) expressed as tumor volume in ILC2 WT (open red circle), ILC2 KO (open blue circle) and ILC2 KO mice
ILC2-transferred (open green circle) (n= 6; *P= 0.0473, **P= 0.0023). c Schematic representation of CRC murine model in Ppargfl/flId2CreERT2 mice.
d Tumor development expressed as tumor volume in Ppargfl/flId2CreERT2 positive (open blue circle) or negative mice (open red circle) (n= 15; *P=
0.0451). e Survival of Ppargfl/flId2CreERT2 positive (blue bar) or negative (red bar) tumor-bearing mice (n= 5; *P= 0.0338). f Expression of Mmp9 (left)
and Ncad (right) assessed by qPCR analysis in Ppargfl/flId2CreERT2 positive (open blue circle) or negative (open red circle) dissociated tumor tissues (n=
8; Mmp9 *P= 0.0379, Ncad *P= 0.0104). Each symbol represents one individual mouse or sample. Data are shown as mean ± SEM and were analyzed by
Log-rank (Mantel–Cox) (a, e) Wilcoxon (f) or two-way (b, d) ANOVA tests. Source data are provided as a Source data file.
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anti‐human CD4 (RPA‐T4, Biolegend, 1:50), Brilliant Violet 785 anti‐human
CD45RO (UCHL1, Biolegend, 1:50), PE-Cy7 anti‐human CXCR3 (1C6, Biolegend,
2:50), PE anti‐human CRTH2 (BM16, Biolegend, 1:50), APC anti‐human CD196
(CCR6) (G034E3, Biolegend, 2:50). Cells were gated on alive CD3+CD4+CD45RO+
cells and the Th subsets were sorted as follow: Th1 as CXCR3+CRTH2−CCR6−, Th2
as CRTH2+, and Th17s as CXCR3−CRTH2−CCR6+.
Murine ILCs were identified as CD45+Lin−CD90.2+ among alive cells. Lineage
markers, all FITC conjugated, include: anti-mouse CD3e (17A2, in house, 1:200),
CD5 (53.7, in house, 1:200), CD19 (ID3, in house, 1:200), CD11b (M1/70, in house,
1:200), CD11c (N418, in house, 1:200), B220 (RA3-6B2, in house, 1:200), CD49b
(DX5, Miltenyi Biotec, 1:200), FCεRIα (MAP-1, Miltenyi Biotec, 2:50), Ter119
(Ter119, in house, 1:200), TCRɣδ (2M31/11, in house, 1:200) and TCRαβ (H57, in
house, 1:200). Additional markers used to identify the ILC subpopulations include:
Alexa-Fluor 700 anti-mouse CD45.2 (AL1-4A2, in house, 1:400), PE anti-mouse
ST2 (RMST2-2, Invitrogen, 1:200), Brilliant Violet 605 anti-mouse CD90.2 (53-2.1,
Biolegend, 1:50), PE-Cy7 anti-mouse KLRG1 (2F1/KLRG1, Biolegend, 1:200), APC
anti-mouse CD117 (cKit) (2B8, eBioscience, 1:200), BV510 anti-mouse NKp46
(29A1.4 Biolegend, 1:100), BV711 anti-mouse NK1.1 (PK136, Biolegend, 1:100),
BUV395 anti-mouse CD4 (GK1.5, BD, 1:200). Representative gating strategy is
included in Supplementary Fig. 7b. Intracellular staining was performed after
fixation and permeabilization with 0.1% saponin (Sigma), using Brilliant Violet 421
anti-mouse IL-5 (TRFK5, Biolegend, 1:50) and PEefluor610 anti-mouse IL-13
(4311635, eBioscience, 1:100).
Cell culture. The murine colon cancer cell line MC-38 was cultured in complete
DMEM GlutaMAX (Gibco) supplemented with 10% FCS (Gibco), 5% penicillin/
streptomycin (Thermo-Fisher), 5% HEPES (Thermo-Fisher), 0.05 mM 2β-
mercaptoethanol (Thermo-Fisher). Human SW1116 colon cancer cells were cul-
tured in RPMI-1640 (Eurobio, Toulouse, France) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) (Eurobio), 2 mM L-glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, 0.01M HEPES buffer and 1 mM sodium pyr-
uvate (Eurobio). Cells were grown until 75% confluency and passaged using trypsin/
1× EDTA (Eurobio), washed with 1× PBS and resuspended in supplemented RPMI-
1640. Expanded ILC2s were cultured in RPMI-1640 (Gibco 61870-010) supple-
mented with 8% human serum, non-essential amino acids (1%, Gibco 11140-035),
sodium pyruvate (1%, Gibco 11360-039), penicillin–streptomycin (1%, Gibco
15140-114), L-glutamine (1%, Gibco 25030-024), kanamycin (0.1 mg/mL, Gibco
15160-054), 2β-mercaptoethanol (0.1%, Sigma-Aldrich M7522), IL-2 (100 U/mL,
Roche) and IL-7 (5 ng/ml, Peprotech). For ILC2 expansion, freshly-sorted ILC2s
were cultured for 2 weeks in supplemented RPMI-1640 with a mixture of IL-2
(100 U/mL), IL-7 (5 ng/ml) and by adding PHA (1 µg/ml) at day 0. Medium was
replaced every 2–3 days and cell phenotype was verified by flow cytometry. When
indicated, IL-33 (50 ng/ml, Adipogen), IL-25 (50 ng/ml, Biolegend), T0070907
(2 µM, Cayman Chemical), Celecoxib (1 µM, Sigma-Aldrich), anti-human IL-13
Antibody (10 µg/ml, Biolegend) and HpARI (1 µg/ml, Adipogen) were added. In
particular, ILC2s were pre-treated with T0070907 for 48 h and then incubated in the
presence of IL-33 and IL-25, or SW1116 CRC cells for an additional 24 or 48 h prior
performing cytokine production analysis by flow cytometry and Legendplex ana-
lysis, respectively. For the evaluation of cytokine production, cells were stimulated
with 1 μg/mL PMA plus 0.5 μg/mL Ionomycin, in the presence of BrefeldinA (all
from Sigma-Aldrich) for 3 h prior to intracellular staining.
CD4+ Th cell subsets were cultured for 2 weeks in supplemented with 100 U/ml
of IL-2 for Th1 and Th2 subsets, or 20 U/ml of IL-2 for the Th17 subset.
Expanded mouse ILC2s were cultured in RPMI-1640 supplemented with 10%
heat-inactivated FBS, IL-2 (100 U/mL) and IL-7 (5 ng/ml). Freshly-sorted ILC2s
from PPARgflox/floxId2-CreERT2 mice were incubated in RPMI-1640 supplemented
with 10% heat-inactivated FBS, IL-2 (100 U/mL), IL-7 (5 ng/ml), IL-33 (50 ng/ml)
and IL-25 (50 ng/ml). After 48 h the supernatant was collected and analyzed to
detect cytokine production by Legendplex analysis.
To generate MC-38-IL-33 cells, we first used HEK-293 cells to produce a
lentivirus encoding Il33, as described previously75. Briefly, HEK-293 cells were
transfected with pMD2G, pMDLg/pRRE, pRSV-Rev, and pLV plasmids (Cyagen
Biosciences, Santa Clara, CA) encoding EGFP with full-length mouse Il33. Next,
lentiviruses were harvested to infect MC-38 cells. Transduced MC-38 cells were
sort-purified based on EGFP expression, which were then kept under antibiotic
selection using 6 μg/ml puromycin for 2 weeks. The procedure was repeated a
second time to select the cells with the highest transgene expression.
SW1116 was purchased from ATCC; MC-38 colon adenocarcinoma cell line
was ordered from Kerafast, Boston, Cat# ENH204 Lot# 011317 (provided by James
W. Hodge, PhD, MBA, National Cancer Institute/NIH). All cell lines were
periodically tested for mycoplasma contamination and confirmed negative by PCR
analysis.
Source of mRNA sequencing data. The expression level of PPAR genes was
assessed using previously published mRNA sequencing data of sorted human ILC
and Th subsets (see Methods in Ercolano et al.1, raw count data per gene and per
sample deposited in the ArrayExpress under accession number E-MTAB-8494).
The raw count data were processed and converted to log2 normalized counts per
million as described in Ercolano et al.1 mRNA sequencing data are deposited in the
ArrayExpress under accession number E-MTAB-8494.
Peroxisome proliferator response element (PPRE) motif search in gene pro-
moters. The promoter sequences (+100 bp up- and downstream flanking regions)
of human or mouse IL-5 and IL-13 were obtained from the Eukaryotic Promoter
Database (human genome version Dec 2013 GRCh38, mouse genome version Mar
2012 mm10; https://epd.epfl.ch//index.php). The consensus sequences of the
binding motif of the human or mouse PPARγ-RXRα heterodimer were down-
loaded from the Jaspar2020 database (matrix IDs: MA0065.1 (human), MA0065.2
(mouse), http://jaspar.genereg.net/). Two methods were used to determine the
presence of the PPRE. First, the findMotifs.pl method of the HOMER software76
(v.4.11, http://homer.ucsd.edu/homer/) and the weight matrix of the most con-
served region of the motif (TCAAAGG for human and CAAGG for mouse) were
used, allowing to search for similar motives with up to 2 mismatches. Second, we
used the online FIMO tool of the MEME suite (v.5.1.1, http://meme-suite.org/
index.html) by providing the complete motif weight matrices and the promoters’
fasta sequences.
Quantitative real-time PCR (qPCR). Total RNA was isolated from highly pure,
sorted human ILC subsets using the TRIZOL reagent according to the manu-
facturer’s instructions (Invitrogen). Final preparation of RNA was considered DNA-
and protein-free if the ratio of readings at 260/280 nm was ≥1.7. Isolated mRNA was
reverse-transcribed by iScript Reverse Transcription Supermix for RT-qPCR (Bio-
Rad, Milan, Italy). The quantitative real-time PCR was carried out in the Applied
Biosystems 7900HT Fast Real-Time PCR Sequence Detection System (Applied
Biosystems) with specific primers (hPPARA 5′-ACGATTCGACTCAAGCTGGT-3′,
5′-CGACAGAAAGGCACTTGTGA-3′; hPPARB 5′-GCATGAAGCTGGAGTAC-
GAGAAG-3′, 5′-GCATCCGACCAAAACGGATA-3′; hPPARG 5′-AAGGCCATTT
TCTCAAACGA-3′, 5′-AGGAGTGGGAGTGGTCTTCC-3′; hIL33 5′-GTGACGGT




AG-3′; mPparg 5′-GTGATGGAAGACCACTCGCATT-3′, 5′-CCATGAGGGAGT
TAGAAGGTTC-3′; mMmp9 5′-GCAGAGGCATACTTGTACCG-3′, 5′-TGATGT
TATGATGGTCCCACTTG-3′; mNcad 5′-CTCCAACGGGCATCTTCATTAT-3′,
5′-CAAGTGAAACCGGGCTATCAG-3′) using KAPA SYBR® FAST qPCR Kits
(Roche). Samples were amplified simultaneously in triplicate in one-assay run with a
non-template control blank for each primer pair to control for contamination or for
primer dimerization, and the Ct value for each experimental group was determined.
The housekeeping genes (ribosomal protein S16 and beta-2-microglobulin (β2M))
were used as an internal control to normalize the Ct values, using the 2−ΔCt formula.
Alternatively, snap-frozen tumor and matched non-tumor tissue from CRC
patients (n= 10+ 10) were homogenized using a TissueLyser (Qiagen) (3 × 30 s at
30 Hz). Total RNA was isolated following the protocol for TRI-reagent (Sigma-
Aldrich) and eluted in 50 μl of water. Total RNA was then reverse-transcribed into
cDNA using a Promega Kit containing M-MLV-RT and Oligo(dT) primers,
following the manufacturer’s protocol.
Preparation of cellular extracts and western blot analysis. Whole-cell extracts
were prepared using RIPA buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100,
1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 1 mM phe-
nylmethylsulfonyl fluoride (PMSF), 1 mM Na3VO4, 5 mM NaF, and 1% cocktail
protease inhibitors; Sigma). The protein concentration was measured by the
Pierce™ BCA Protein Assay Kit (Thermo Scientific). Equal amounts of protein (40
µg/sample) were separated by electrophoresis in a 12% denatured polyacrylamide
gel and blotted onto nitrocellulose membranes (Biorad). The membranes were
blocked for 1 h in 5% low-fat milk in 1× PBS with 0.1% Tween20 (PBST) at room
temperature. The filters were then incubated overnight at +4 °C with the following
primary antibodies: PPARɣ (2443, Cell Signaling, diluted 1:1000) and α-Tubulin
(3873, Cell Signaling, diluted 1:1000). The membranes were washed 3 times for 10
min with PBST and then incubated with HRP-conjugated anti-rabbit or anti-
mouse antibodies (Biolegend) for 2 h at room temperature. The membranes were
then washed for 3 times for 10 min in PBST, and proteins were visualized by the
ECL chemiluminescence method. The immunoreactive bands of proteins were
acquired using GBOX Chemi XX6 system (Syngene).
PPARγ small interfering RNA transfection of ILC2s. For the silencing experi-
ments, expanded ILC2s were seeded in 96-well plates (2 × 104 cell/well) and
transfected the next day, according to the manufacturer’s instruction, with PPARG
Trilencer-27 Human siRNA (OriGene, Rockville, MD, USA) (rGrGrArArUrUrAr
GrA rUrGrArCrArGrCrGrArCrUrUrGrGCA; rUrCrCrGrGrArGrArArCrArArUr
CrArGrArUrUrUrGrArArGCT; rArGrArArCrArGrArUrCrCrArGrUrGrGrUrUr
GrCrArGrATT). The final concentration of the siRNA pool was 10 nM. 48 h after
transfection, IL-13 and IL-5 production and secretion was evaluated by flow
cytometry and Legendplex analysis, respectively. The knockdown of PPARγ
expression in cells after transfection was confirmed by qPCR analysis. The Uni-
versal scrambled negative control siRNA duplex was used as negative control.
ChIP assay. Expanded human ILC2s were cross-linked with 1% formaldehyde for
15 min. Chromatin was sheared by sonification with Bioruptor Pico (30” on and
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30” off for 25 cycles) and immunoprecipitated with anti-PPARγ (5 µg, Diagenode)
or an isotype control IgG using MAGnify Chromatin Immunoprecipitation system
(Thermo Fisher). Eluted DNA was used for qPCR analysis using IL-13 primers
(5′-GAAGGCTCCGCTCTGCAAT-3′, 5′-TCCAGGGCTGCACAGTACA-3′).
Electron microscopy (EM). Sorted cells were fixed in glutaraldehyde solution
(EMS, Hatfield, PA, US) 2.5% in phosphate buffer (PB 0.1 M pH7.4) (Sigma, St
Louis, MO, US) during 1 h at room temperature (RT). Then, they were directly
post-fixed by a fresh mixture of osmium tetroxide 1% (EMS, Hatfield, PA, US) with
1.5% of potassium ferrocyanide (Sigma, St Louis, MO, US) in PB buffer during 1 h
at RT. The samples were then washed three times in distilled water and dehydrated
in acetone solution (Sigma, St Louis, MO, US) at graded concentrations (30%—40
min; 50%—40 min; 70%—40 min; 100%—3×1 h). This was followed by infiltration
in Epon (Sigma, St Louis, MO, US) at graded concentrations (Epon 1/3 acetone-2h;
Epon 3/1 acetone-2h, Epon 1/1-4 h; Epon 1/1-12 h) and finally polymerized for
48 h at 60 °C in the oven. Ultrathin sections of 50 nm were cut on a Leica Ultracut
(Leica Mikrosysteme GmbH, Vienna, Austria) and picked up on a copper slot grid
2×1 mm (EMS, Hatfield, PA, US) coated with a polystyrene film (Sigma, St Louis,
MO, US). Sections were post-stained with uranyl acetate (Sigma, St Louis, MO, US)
4% in H2O during 10 min, rinsed several times with H2O followed by Reynolds
lead citrate in H2O (Sigma, St Louis, MO, US) during 10 min and rinsed several
times with H2O. Micrographs were taken at a magnification of 4800X with a
transmission electron microscope Philips CM100 (Thermo Fisher Scientific,
Waltham, MA USA) at an acceleration voltage of 80 kV with a TVIPS TemCam-
F416 digital camera (TVIPS GmbH, Gauting, Germany) using EMMENU software
and exported in 8bits. The acquisition and analysis of the images were performed
double-blinded using 3dmod and its stereology plugin77. Briefly, a grid was applied
on each cell and each intersection was defined as being part of the nucleus,
cytoplasm or mitochondria, allowing to determine the percentage of mitochondrial
volume per ILC2.
Multiplex cytokine assay. The concentrations of various cytokines in
ILC2 supernatants, healthy donor’s and patient’s sera were determined using the
multi-LEGENDplex™ analyte flow assay kit (human and mouse Th Panel (13-plex),
Biolegend). Briefly, antibodies specific for the 13 analytes were conjugated to 13
different fluorescence-encoded beads. The beads were mixed with the supernatants,
incubated for 2 h at room temperature, washed, and incubated for 1 h with
detection antibodies. Finally, streptavidin-PE was added and incubated for 30 min,
and the beads were washed and acquired using Gallios. The results were analyzed
by using the Legendplex software (version 8.0).
ELISA. IL-33 plasma concentrations were evaluated using ELISA kit according to
the manufacturer’s instruction (LEGEND MAX™ Human IL-33 ELISA Kit,
Biolegend).
IHC. Human CRC tissues were fixed in 4% formaldehyde and embedded in par-
affin. Staining reactions were performed by automated staining using a BOND RX
autostainer (Leica Biosystems). For double immunohistochemistry staining, sec-
tions were first deparaffinized and antigen was retrieved using 1 mM Tris solution
(pH 9.0) for 30 min at 95 °C. Sections were then stained with goat anti-human IL-
33 (R&D Systems, # AF3625; dilution of 1:400) and anti-human CD3 (abcam, #
ab16669; dilution of 1:400) or anti-human IL-33 and anti-human GATA3 (Cell
Marque, #390M-14; dilution of 1:400) primary antibodies. A rabbit anti-goat
antibody (Agilent, # E0466) was used as secondary antibody, at a dilution of 1:400.
Specific binding of primary antibodies was visualized using a polymer-based
visualizing system with horseradish peroxidase as the enzyme and 3,3-diamino-
benzidine (DAB) as a brown chromogen, or an alkaline phosphatase-linked
polymer and Fast Red as red chromogen (Bond™ Polymer Refine and Red Detec-
tion), respectively (all from Leica Biosystems). The samples were counterstained
with hematoxylin and mounted with Aquatex (Merck). Slides were scanned in high
resolution on whole slide scanners Pannoramic 250 Flash (3DHISTECH) or
NanoZoomer S360 (Hamamatsu). All human CRC tissues were provided by the
Tissue Bank Bern.
Image processing. Each TMA image was dearrayed and individual cores exported
as PNG using QuPath78. Color deconvolution was performed using ImageJ (Ver-
sion 1.52p)79 and it’s “color deconvolution” plugin80 resulting in three individual
channels for hematoxylin, IL33 and CD3 or GATA3, respectively. Since the CD3
and GATA3 stainings were performed on serial section, they could be co-registered
using the ImageJ plugin “burwarpJ”81 based on the hematoxylin channel.
In vitro co-culture experiments. Expanded ILC2s from healthy donors were
pretreated with T0070907 PPARγ antagonist for 48 h and then cultured with the
SW1116 colon cancer cell line in a ratio of 1:1. After 48 h, ILC2s were harvested
and analyzed to detect cytokine production by flow cytometry analysis.
Preparation of ILC2 conditioned medium (CM). Expanded ILC2s were pre-
treated or not with T0070907 PPARγ antagonist for 48 h and then stimulated with
IL-33 and IL-25 (50 ng/ml). After 48 h the medium was collected, centrifuged at
250 × g for 5 min and filtered through a 0.22-μm syringe filter.
Wound healing assay. SW1116 cells were seeded in 24-well plates (3 × 105 cells/
well). Once the cells reached 90% confluence, ILC2 or ILC2+ T0070907 CM (30%
v/v) were added and a wound area was carefully created by scraping the cell
monolayer with a sterile 200 μl pipette tip. Subsequently, the cells were incubated at
37 °C in 5% CO2. The width of the wounded area was monitored and photo-
graphed with an inverted microscope at various time points (20-fold magnifica-
tion). The wounded area was measured using Image J software (LASV3.8,
Germany).
Growth rate analysis. Cell growth rate was determined by MTT (3-(4,3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide) assay. Briefly, SW1116 cells were seeded in 96-
well plates (5 × 103 cells/well) and incubated for 24, 48, and 72 h with ILC2 or
ILC2+ T0070907 CM (30% v/v) before adding 25 µL MTT (Sigma-Aldrich; 5 mg/
mL in saline). Cells were then incubated for additional 3 h at 37 °C. After this time
interval, dark blue crystals were solubilized with pure DMSO. The optical density
of each well was measured with a microplate spectrophotometer (TitertekMultis-
kan MCC/340), equipped with a 540-nm filter.
Clonogenic assay. SW1116 cells (1 × 103 cells/well) were seeded in 6-well plates with
ILC2, ILC2+ T0070907 CM (30% v/v) or ILC2 CM with anti-IL-13 blocking anti-
body (IL13i). Cells were cultured for 14 days to allow the colonies to form. Formed
colonies were washed twice with 1xPBS, fixed by 4% paraformaldehyde, and stained
with 0.5% crystal violet and colonies containing more than 50 cells (established by
microscopy) were counted manually. Images of the colonies were obtained using a
digital camera. The experiments were done at least three times, in duplicate.
In vivo tumor models. PPARγflox/flox mice82 were backcrossed to C57BL/683 and
crossed in house with Id2-CreERT2 (Jackson Laboratory, Stock number 016222).
To induce the deletion of PPARγ after intraperitoneal (i.p.) tamoxifen adminis-
tration. RORαfl/sgIl7rCre mice were kindly provided by Prof. A. McKenzie45.
PPARγflox/floxId2-CreERT2 and RORαfl/sgIl7rCre mice and littermates, were
between 6- and 12-weeks age and bred in house. All our mouse strains are in a
C57BL/6 genetic background. 5 × 105 MC-38-IL33 murine colorectal cancer cells
were injected subcutaneously (s.c.) in 200 µL of 1× PBS in the right flank and
tumor growth was monitored. When indicated, T0070907 (7.5 mg/kg, Cayman
Chemical), anti-IL13 neutralizing antibodies (50 µg/mouse, InvivoGen) and Isotype
controls (50 µg/mouse, Bxcell) were daily injected intraperitoneally (i.p.) for
18 days. For ILC2 adoptive transfer, donor mice were injected with 0.4 µg of IL-25
and IL-33 for induction of ILC2s. 3 days after injection, flow cytometry-purified
donor lung ILC2s were expanded in vitro (see Cell Culture) before 2.5 × 105
intravenous (i.v.) injection into RORafl/sgIl7rCre mice. Tumor sizes were measured
using a digital caliper and tumor volumes were calculated using the following
equation: tumor volume=Π/6(D1 ×D2 ×D3) where D1= length; D2=width;
D3 = height and expressed as cm3. We have complied with all relevant ethical
regulations for animal testing and research. This study was approved by the
Veterinary Authority of the Swiss Canton Vaud (authorization no. VD3255.f) and
performed in accordance with Swiss ethical guidelines. All animals were main-
tained at the University of Lausanne’s animal facility under a 12 h dark/light cycle,
at 21 °C ± 1 °C and 55% ± 10% HR.
Statistical analysis. Statistical analysis was performed using GraphPad Prism
software version 6. For comparison of two groups the t test was used, for com-
parison of multiple groups ANOVAs or the non-parametric (Mann–Whitney or
Kruskal–Wallis tests) tests were used. The data are shown by plotting individual
data points and the mean ± SEM. A p value < 0.05 (two-tailed) was considered
statistically significant and labeled with *p values < 0.01, 0.001 or 0.0001 were
labeled with **, *** or ****, respectively.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA-seq data used in this study are deposited in the ArrayExpress under accession
number E-MTAB-8494. Proteins putatively involved in protein–protein interactions
were taken from the STRING database. The promoter sequences (+100 bp up- and
downstream flanking regions) of human or mouse IL-5 and IL-13 were obtained from
the Eukaryotic Promoter Database (human genome version Dec 2013 GRCh38, mouse
genome version Mar 2012 mm10; https://epd.epfl.ch//index.php). The consensus
sequences of the binding motif of the human or mouse PPARγ-RXRα heterodimer were
downloaded from the Jaspar2020 database (matrix IDs: MA0065.1 (human), MA0065.2
(mouse), http://jaspar.genereg.net/). Source data are available as a Source data file. The
remaining data are available within the Article, Supplementary Information or available
from the authors upon request.
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